Nukkleus Inc. (NASDAQ:DFNS – Get Free Report) was the target of a large decrease in short interest in August. As of August 14th, there was short interest totaling 144,490 shares, a decrease of 48.2% from the July 30th total of 279,125 shares. Based on an average daily volume of 2,406,740 shares, the short-interest ratio is presently 0.1 days. Approximately 16.1% of the company’s stock are short sold.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its stake in shares of Nukkleus by 193.7% in the fourth quarter. Geode Capital Management LLC now owns 124,714 shares of the company’s stock worth $503,000 after buying an additional 82,252 shares in the last quarter. UBS Group AG grew its stake in shares of Nukkleus by 23.3% in the third quarter. UBS Group AG now owns 80,512 shares of the company’s stock worth $564,000 after acquiring an additional 15,223 shares during the period. LPL Financial LLC purchased a new position in shares of Nukkleus during the fourth quarter valued at approximately $120,000. Engineers Gate Manager LP purchased a new position in shares of Nukkleus during the fourth quarter valued at approximately $96,000. Finally, State Street Corp lifted its position in Nukkleus by 70.7% during the fourth quarter. State Street Corp now owns 17,863 shares of the company’s stock valued at $72,000 after purchasing an additional 7,400 shares during the period. 12.47% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on DFNS shares. Weiss Ratings lowered Nukkleus from a “sell (d+)” rating to a “sell (e+)” rating in a research report on Monday, July 20th. Wall Street Zen upgraded shares of Nukkleus from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 23rd. Finally, Noble Financial upgraded shares of Nukkleus to a “strong-buy” rating in a report on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.
Nukkleus Stock Performance
Shares of DFNS opened at $11.82 on Tuesday. The stock’s 50-day simple moving average is $23.30 and its 200 day simple moving average is $78.56. The stock has a market capitalization of $19.62 million, a price-to-earnings ratio of -0.03 and a beta of -5.80. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.11 and a current ratio of 0.14. Nukkleus has a 52-week low of $3.70 and a 52-week high of $1,948.75.
Nukkleus (NASDAQ:DFNS – Get Free Report) last issued its quarterly earnings results on Wednesday, August 19th. The company reported ($173.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.11) by ($170.69). The firm had revenue of $4.00 million during the quarter, compared to analysts’ expectations of $4.50 million. Research analysts forecast that Nukkleus will post -3.9 EPS for the current fiscal year.
Nukkleus Company Profile
Nukkleus Inc, a financial technology company, provides blockchain-enabled technology solutions worldwide. It focuses on providing software and technology solutions for retail foreign exchange trading industry. The company provides transactions platform for dealing and risk management services. It also offers cross-border payment and transactions solutions and blockchain-enabled financial services solutions to institutional investors. In addition, the company provides software, technology, customer sales and marketing, and risk management technology hardware and software solutions.
See Also
- Five stocks we like better than Nukkleus
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Nukkleus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nukkleus and related companies with MarketBeat.com's FREE daily email newsletter.
